Advertisement


David E. Gerber, MD, and James L. Mulshine, MD, on Bringing Genomic Discovery and Targeted Therapies to Early-Stage Lung Cancer

2015 ASCO Annual Meeting

Advertisement

James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).



Related Videos

Lymphoma

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Lung Cancer

Luis G. Paz-Ares, MD, PhD, Summarizes Results of the CheckMate 057 Trial on Nonsquamous Cell NSCLC

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario Doce De Octubre, discusses the superior overall survival in patients taking nivolumab vs docetaxel in advanced nonsquamous NSCLC (Abstract LBA109).

Prostate Cancer

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).

Issues in Oncology
Cost of Care

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Charles L. Bennett, MD, PhD, MPP of the University of South Carolina College of Pharmacy, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss the emerging and future benefits of biosimilars.

Breast Cancer

Jame Abraham, MD, Summarizes Results From the NeoSphere and ExteNET Trials for Breast Cancer

Jame Abraham, MD, of the Cleveland Clinic discusses analyses of two trials for locally advanced, inflammatory, or early HER2-positive breast cancer using docetaxel, trastuzumab, pertuzumab, and neratinib (Abstracts 505 and 508).

Advertisement

Advertisement




Advertisement